HIGHLIGHTS

2387  Selected Articles from This Issue

COMMENTARY

2389  Translating Cancer Risk Prediction Models into Personalized Cancer Risk Assessment Tools: Stumbling Blocks and Strategies for Success
  Erika A. Waters, Jennifer M. Taber, Amy McQueen, Ashley J. Houston, Jamie L. Studts, and Laura D. Scherer

CEBP FOCUS

2396  The National Cancer Institute Early Detection Research Network: Two Decades of Progress
  A C  Robert C. Bast Jr and Sudhir Srivastava

2401  The Early Detection Research Network: A National Infrastructure to Support the Discovery, Development, and Validation of Cancer Biomarkers
  A C  Sudhir Srivastava and Paul D. Wagner

2411  Biomarkers for Lung Cancer Screening and Detection
  A C  Edwin J. Ostrin, David Sidransky, Avrum Spira, and Samir M. Hanash

2416  Noninvasive Diagnostics for Early Detection of Lung Cancer: Challenges and Potential with a Focus on Changes in DNA Methylation
  A C  Maria Farooq and James G. Herman

2423  Lung Cancer and Immunity Markers
  A C  Raymond J. Lim, Bin Liu, Kostyantyn Krysan, and Steven M. Dubinett

2431  Biomarkers for Early Detection of Colorectal Cancer: The Early Detection Research Network, a Framework for Clinical Translation
  A C  Robert S. Bresalier, William M. Grady, Sanford D. Markowitz, Hans Jørgen Nielsen, Surinder K. Batra, and Paul D. Lampe

2441  Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia
  A C  Joshua D. Cohen, Brenda Diergaarde, Nickolas Papadopoulos, Kenneth W. Kinzler, and Robert E. Schoen

2454  Prostate Cancer Biomarker Development: National Cancer Institute’s Early Detection Research Network Prostate Cancer Collaborative Group Review
  A C  Michael A. Liss, Robin J. Leach, Martin G. Sanda, and Oliver J. Semmes

2463  The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment
  A C  Kelly Hewitt, Jennifer Son, Alexa Glencer, Alexander D. Borowsky, Matthew R. Cooperberg, and Laura J. Esserman

2475  Autoantibodies in Early Detection of Breast Cancer
  A C  Femina Rauf, Karen S. Anderson, and Joshua LaBaer

2486  Barrett’s Esophagus and Esophageal Adenocarcinoma Biomarkers
  A C  William M. Grady, Ming Yu, Sanford D. Markowitz, and Amitabh Chak

2495  Biomarkers for the Early Detection of Hepatocellular Carcinoma
  A C  Neelhar D. Parikh, Anand S. Mehta, Amit G. Singal, Timothy Block, Jorge A. Marrero, and Anna S. Lok

2504  Biomarkers and Strategies for Early Detection of Ovarian Cancer

2513  Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN
  A C  Ying Liu, Sukhwinder Kaur, Ying Huang, Johannes F. Fahrmann, Jo Ann Rinaudo, Samir M. Hanash, Surinder K. Batra, Aatur D. Singh, Randall E. Brand, Anirban Maitra, and Brian B. Haab
TABLE OF CONTENTS

2524 Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network

AC Harvey I. Pass, Marjan Alimi, Michele Carbone, Haining Yang, and Chandra M. Goparaju

2541 The Potential of Circular RNAs as Cancer Biomarkers

AC Jason R. Brown and Arul M. Chinnaiyan

2556 Radiomics Improves Cancer Screening and Early Detection

AC Robert J. Gillies and Matthew B. Schabath

2568 Pitfalls in Cancer Biomarker Discovery and Validation with Emphasis on Circulating Tumor DNA

AC Annie H. Ren, Clare A. Fiala, Eleftherios P. Diamandis, and Vathany Kulasingam

2575 Adding Rigor to Biomarker Evaluations—EDRN Experience

AC Ziding Feng and Margaret S. Pepe


AC Jessica Y. Islam, Marlene Camacho-Rivera, and Denise C. Vidot

2591 Premature Years of Life Lost Due to Cancer in the United States in 2017

AC Minkyo Song, Allan Hildesheim, and Meredith S. Shiels

2599 Strategizing Screening for Melanoma in an Era of Novel Treatments: A Model-Based Approach

AC Kemal Caglar Gogebakan, Elizabeth G. Berry, Alan C. Geller, Kemal Sonmez, Sancy A. Leachman, and Ruth Etzioni

2608 Daily Physical Activity and Symptom Reporting in Breast Cancer Patients Undergoing Chemotherapy: An Intensive Longitudinal Examination


2617 Associations of Leisure-Time Physical Activity and Television Viewing with Life Expectancy Cancer-Free at Age 50: The ARIC Study

AC Carmen Cuthbertson, Hazel B. Nichols, Xianming Tan, Anna Kucharska-Newton, Gerardo Heiss, Corinne E. Joshu, Elizabeth A. Platz, and Kelly R. Evenson

2626 Community-Acquired Escherichia coli Bacteremia after Age 50 and Subsequent Incidence of a Cancer Diagnosis: A Danish Population-Based Cohort Study

AC Kirstine K. Sogaard, Katalin Veres, Christina M.J.E. Vandenbroucke-Grauls, Jan P. Vandenbroucke, Henrik T. Sørensen, and Henrik C. Schønheyder

2633 Low Levels of Alcohol Consumption and Risk of Intestinal Metaplasia: A Cohort Study

AC Kyungeun Kim, Yoosoo Chang, Jiin Ahn, Hyo-Joon Yang, and Seungho Ryu

2642 Methylated DNA Markers of Esophageal Squamous Cancer and Dysplasia: An International Study


2651 Extended HPV Genotyping to Compare HPV Type Distribution in Self- and Provider-Collected Samples for Cervical Cancer Screening


2662 HPV Types in Cervical Precancer by HIV Status and Birth Region: A Population-Based Register Study

AC Christina Carlander, Camilla Lagheden, Carina Eklund, Sara Nordqvist Kleppe, Mensur Dzabic, Philippe Wagner, Aylin Yilmaz, Kristina Elfgren, Anders Sönnerborg, Pär Sparén, and Joakim Dillner

2669 Association between Receipt of Guideline-Concordant Lung Cancer Treatment and Individual- and Area-Level Factors: A Spatio-Temporal Analysis

AC Win Wah, Rob G. Stirling, Susannah Ahern, and Arul Earnest

2680 A Large Cohort Study of Body Mass Index and Pancreatic Cancer by Smoking Status

AC Eric J. Jacobs, Christina C. Newton, Victoria L. Stevens, Alpa V. Patel, W. Dana Flanders, and Susan M. Gapstur

2686 Replication and Genetic Risk Score Analysis for Pancreatic Cancer in a Diverse Multiethnic Population

AC David Bogumil, David V. Conti, Xin Sheng, Lucy Xia, Xiao-ou Shu, Stephen J. Pandol, William J. Blot, Wei Zheng, Loic Le Marchand, Christopher A. Haiman, and Veronica Wendy Setiawan
Glucosamine and Chondroitin Supplements and Risk of Colorectal Adenoma and Serrated Polyp
Dong Hoon Lee, Chao Cao, Xiaoyu Zong, Xuehong Zhang, Kelli O’Connell, Mingyang Song, Kun Wu, Mengmeng Du, Yin Cao, Edward L. Giovannucci, and Elizabeth D. Kantor

Evaluation of Circulating Tumor DNA for Methylated BCAT1 and IKZF1 to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC)
Benjamin L. Musher, Joshua E. Melson, Gianni Amato, David Chan, Marisa Hill, Iftekhar Khan, Joel Saltzman, Jennifer Silinsky, Snigdha Gaur, Melissa K. Tuck, Lawrence C. LaPointe, and Graeme P. Young

Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States
Natalia Kunst, Fernando Aralid-Escudero, Eline Aas, Veele M.H. Coupé, Deborah Schrag, and Karen M. Kuntz

Genetic Variants in the Regulatory T cell–Related Pathway and Colorectal Cancer Prognosis

Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium

Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk

The Role of Dissemination and Implementation Research in Global Tobacco Control: A Report from the American Society of Preventive Oncology
Ramzi G. Salloum, Mark Parascandola, Jennifer H. LeLaurin, and Donna Shelley
ABOUT THE COVER

The cover image is adapted from Figure 3 in the article, "Prostate Cancer Biomarker Development: National Cancer Institute’s Early Detection Research Network Prostate Cancer Collaborative Group Review," by Liss and colleagues. The figure shows an MRI-Ultrasound Fusion-guided technique for targeted prostate biopsy. Prostate cancer remains the most common non-skin cancer and second leading cause of death among men in the United States. Although progress has been made in diagnosis and risk assessment, many clinical questions remain regarding early identification of prostate cancer and management. The early detection of aggressive disease continues to provide high curative rates if diagnosed in a localized state. Unfortunately, prostate cancer displays significant heterogeneity within the prostate organ and between individual patients, making detection and treatment strategies complex. Although prostate cancer is common among men, the majority will not die from prostate cancer, introducing the issue of overtreatment as a major concern in clinical management of the disease. The focus of the future is to identify those at highest risk for aggressive prostate cancer and to develop prevention and screening strategies, as well as discerning the difference in malignant potential of diagnosed tumors. The Prostate Cancer Research Group of the National Cancer Institute’s Early Detection Research Network (EDRN) has contributed to the progress in addressing these concerns. The strong focus on biomarker application optimizes the development of biomarkers with clinical utility as well as the early adoption of disruptive technologies, such as MRI imaging, into biomarker development workflows. Likewise, efforts to validate findings from laboratories outside of the EDRN, such as polygenic risk scores and capture of in-depth data from clinical cohorts provide unique resources to the biomarker community. For more information, see the article beginning on page 2454.